ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,430.40
      0.14%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      85.05
      0.31%
      Bitcoin
      65,156.62
      0.03%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Atara Biotherapeutics Inc (ATRA)

      7. Atara Biotherapeutics Inc (ATRA) News

      ATRA

      Atara Biotherapeutics (ATRA)

      Atara Biotherapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ATRA
      DateTimeSourceHeadlineSymbolCompany
      03/06/20236:47PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATRAAtara Biotherapeutics Inc
      03/03/20235:17PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATRAAtara Biotherapeutics Inc
      03/03/20235:16PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATRAAtara Biotherapeutics Inc
      03/03/20235:16PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATRAAtara Biotherapeutics Inc
      03/03/20235:16PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATRAAtara Biotherapeutics Inc
      03/03/20234:01PMBusiness WireAtara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
      03/01/20234:01PMBusiness WireAtara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
      02/21/20234:01PMBusiness WireAtara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
      02/14/20234:10PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ATRAAtara Biotherapeutics Inc
      02/14/20237:32AMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ATRAAtara Biotherapeutics Inc
      02/14/20236:23AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ATRAAtara Biotherapeutics Inc
      02/09/20235:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATRAAtara Biotherapeutics Inc
      02/09/202311:11AMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ATRAAtara Biotherapeutics Inc
      02/09/20238:25AMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ATRAAtara Biotherapeutics Inc
      02/09/20236:04AMEdgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:ATRAAtara Biotherapeutics Inc
      02/09/20236:00AMEdgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ATRAAtara Biotherapeutics Inc
      02/08/20234:56PMEdgar (US Regulatory)Annual Report (10-k)NASDAQ:ATRAAtara Biotherapeutics Inc
      02/08/20234:01PMBusiness WireAtara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational ProgressNASDAQ:ATRAAtara Biotherapeutics Inc
      02/08/20236:00AMBusiness WirePierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)NASDAQ:ATRAAtara Biotherapeutics Inc
      02/06/20238:00AMBusiness WireAtara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023NASDAQ:ATRAAtara Biotherapeutics Inc
      02/03/20234:01PMBusiness WireAtara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
      01/24/20232:01PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ATRAAtara Biotherapeutics Inc
      01/13/20234:01PMBusiness WireAtara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
      01/06/20234:17PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ATRAAtara Biotherapeutics Inc
      01/04/20234:01PMBusiness WireAtara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
      12/20/20224:43PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ATRAAtara Biotherapeutics Inc
      12/20/20224:33PMBusiness WireAtara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare RoyaltyNASDAQ:ATRAAtara Biotherapeutics Inc
      12/19/20228:06AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ATRAAtara Biotherapeutics Inc
      12/19/20228:00AMBusiness WireAtara Biotherapeutics Announces Changes to Its Board of DirectorsNASDAQ:ATRAAtara Biotherapeutics Inc
      12/19/20227:00AMPR Newswire (US)Atara Biotherapeutics' Ebvallo® (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLDNASDAQ:ATRAAtara Biotherapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:ATRA